Weight loss drug FDA regulations | KTVU

preview_player
Показать описание
In April, the Food and Drug Administration will restrict who can make and sell popular weight-loss medications known as GLP-1s.

In 2022, weight-loss drugs like Ozempic, Wegovy and others experienced a surge in popularity.

In order to meet skyrocketing demand, the FDA gave permission to compounding pharmacies to make non-brand name copies of those drugs.

The FDA now says the manufacturers of brand-name drugs have caught up, and starting April 22, special permission for compounding pharmacies will be revoked.

Рекомендации по теме
Комментарии
Автор

This is wrong! You can’t keep patents on a peptide.

angelag
Автор

Um, no it hasn't... I cant get most doses of Ozempic, Wegovy, Mounjaro, Zepbound from our suppliers; McKesson, ABC, Cardinal.... this story conveniently left this out...

LinkHylia
join shbcf.ru